References
1. World Health Organization. Global strategy to accelerate the
elimination of cervical cancer as a public health problem. Published
online January 3, 2020.2. Arbyn M, Ronco G, Anttila A, et al. Evidence
Regarding Human Papillomavirus Testing in Secondary Prevention of
Cervical Cancer. Vaccine . 2012;30:F88-F99.
doi:10.1016/j.vaccine.2012.06.0953. Arbyn M, Gultekin M, Morice P, et
al. The European response to the WHO call to eliminate cervical
cancer as a public health problem. Intl Journal of Cancer .
2021;148(2):277-284. doi:10.1002/ijc.331894. Kyrgiou M, Arbyn M,
Bergeron C, et al. Cervical screening: ESGO-EFC position paper of the
European Society of Gynaecologic Oncology (ESGO) and the European
Federation of Colposcopy (EFC). Br J Cancer . 2020;123(4):510-517.
doi:10.1038/s41416-020-0920-95. Arbyn M, Verdoodt F, Snijders PJF, et
al. Accuracy of human papillomavirus testing on self-collected versus
clinician-collected samples: a meta-analysis. The Lancet
Oncology . 2014;15(2):172-183. doi:10.1016/S1470-2045(13)70570-96. Arbyn
M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer
and reaching underscreened women by using HPV testing on self samples:
updated meta-analyses. BMJ . Published online December 5,
2018:k4823. doi:10.1136/bmj.k48237. Serrano B, Ibáñez R, Robles C,
Peremiquel-Trillas P, de Sanjosé S, Bruni L. Worldwide use of HPV
self-sampling for cervical cancer screening. Preventive Medicine .
2022;154:106900. doi:10.1016/j.ypmed.2021.1069008. Arbyn M, Simon M,
Peeters E, et al. 2020 list of human papillomavirus assays suitable for
primary cervical cancer screening. Clinical Microbiology and
Infection . 2021;27(8):1083-1095. doi:10.1016/j.cmi.2021.04.0319. Arbyn
M, Peeters E, Benoy I, et al. VALHUDES: A protocol for validation of
human papillomavirus assays and collection devices for HPV testing on
self-samples and urine samples. Journal of Clinical Virology .
2018;107:52-56. doi:10.1016/j.jcv.2018.08.00610. Latsuzbaia A, Vanden
Broeck D, Van Keer S, et al. Comparison of the Clinical Accuracy of
Xpert HPV Assay on Vaginal Self-Samples and Cervical Clinician-Taken
Samples within the VALHUDES Framework. The Journal of Molecular
Diagnostics . 2023;25(9):702-708. doi:10.1016/j.jmoldx.2023.06.00411.
Latsuzbaia A, Van Keer S, Vanden Broeck D, et al. Clinical Accuracy of
Alinity m HR HPV Assay on Self- versus Clinician-Taken Samples Using the
VALHUDES Protocol. The Journal of Molecular Diagnostics .
2023;25(12):957-966. doi:10.1016/j.jmoldx.2023.09.00812. Latsuzbaia A,
Vanden Broeck D, Van Keer S, et al. Clinical Performance of the RealTim e High Risk HPV Assay on Self-Collected Vaginal Samples within
the VALHUDES Framework. Lainhart W, ed. Microbiol Spectr .
2022;10(5):e01631-22. doi:10.1128/spectrum.01631-2213. Latsuzbaia A,
Vanden Broeck D, Van Keer S, et al. Validation of BD Onclarity HPV Assay
on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES
Protocol. Cancer Epidemiology, Biomarkers & Prevention .
2022;31(12):2177-2184. doi:10.1158/1055-9965.EPI-22-075714. Van Keer S,
Latsuzbaia A, Vanden Broeck D, et al. Analytical and clinical
performance of extended HPV genotyping with BD Onclarity HPV Assay in
home-collected first-void urine: A diagnostic test accuracy study.J Clin Virol . 2022;155:105271. doi:10.1016/j.jcv.2022.10527115.
Van Keer S, Peeters E, Vanden Broeck D, et al. Clinical and analytical
evaluation of the RealTime High Risk HPV assay in Colli-Pee collected
first-void urine using the VALHUDES protocol. Gynecol Oncol .
2021;162(3):575-583. doi:10.1016/j.ygyno.2021.06.01016. Dhillon SK,
Cocuzza CE, Chung PYJ, et al. Evaluation of the clinical performance of
OncoPredict HPV® SCR assay within the VALGENT‐2 framework. Journal
of Medical Virology . 2023;95(1):e28417. doi:10.1002/jmv.2841717. Arbyn
M, Bruni L, Kelly D, et al. Tackling cervical cancer in Europe amidst
the COVID-19 pandemic. The Lancet Public Health . 2020;5(8):e425.
doi:10.1016/S2468-2667(20)30122-518. Martinelli M, Latsuzbaia A, Bonde
J, et al. Performance of BD Onclarity HPV assay on FLOQSwabs vaginal
self-samples. Starolis M, ed. Microbiol Spectr .
2024;12(3):e02872-23. doi:10.1128/spectrum.02872-2319. Arbyn M, Costa S,
Latsuzbaia A, et al. HPV-based Cervical Cancer Screening on Self-samples
in the Netherlands: Challenges to Reach Women and Test Performance
Questions. Cancer Epidemiology, Biomarkers & Prevention .
2023;32(2):159-163. doi:10.1158/1055-9965.EPI-22-104120. Juliana NCA,
Juma MH, Heijmans R, et al. Detection of high-risk human papillomavirus
(HPV) by the novel AmpFire isothermal HPV assay among pregnant women in
Pemba Island, Tanzania. Pan Afr Med J . 2020;37.
doi:10.11604/pamj.2020.37.183.2336721. Seyoum A, Seyoum B, Gure T, et
al. Genotype heterogeneity of high-risk human papillomavirus infection
in Ethiopia. Front Microbiol . 2023;14:1116685.
doi:10.3389/fmicb.2023.111668522. Giubbi C, Martinelli M, Vallini I, et
al. Human papillomavirus (HPV) detection in vaginal self-samples:
evaluation of eNat® as an alternative suspension medium to
ThinPrep®PreservCyt® for vaginal swabs. Open Res Europe .
2022;2:35. doi:10.12688/openreseurope.14344.223. Giubbi C, Martinelli M,
Di Meo ML, et al. Evaluation of two alternative non-alcohol-based media
for the suspension of self-collected vaginal swabs for HPV testing in
cervical cancer screening. Heliyon . 2024;10(10):e31032.
doi:10.1016/j.heliyon.2024.e3103224. De Pauw H, Donders G, Weyers S, et
al. Cervical cancer screening using HPV tests on self-samples: attitudes
and preferences of women participating in the VALHUDES study. Arch
Public Health . 2021;79(1):155. doi:10.1186/s13690-021-00667-425.
Pasquier C, Raymond S, Duchanois D, et al. Human papillomavirus testing
using HPV APTIMA® assay and an external cellularity control in
self‐collected samples. Journal of Medical Virology .
2023;95(12):e29283. doi:10.1002/jmv.2928326. Brukner I, Eintracht S,
Papadakis AI, et al. Maximizing confidence in a negative result:
Quantitative sample adequacy control. Journal of Infection and
Public Health . 2020;13(7):991-993. doi:10.1016/j.jiph.2020.01.30727.
Brukner I, Resendes A, Eintracht S, Papadakis A, Oughton M. Sample
Adequacy Control (SAC) Lowers False Negatives and Increases the Quality
of Screening: Introduction of “Non-Competitive” SAC for qPCR Assays.Diagnostics . 2021;11(7):1133. doi:10.3390/diagnostics1107113328.
Cocuzza CE, Dhillon SK, Martinelli M, et al. Clinical performance of the
novel full‐genotyping OncoPredict HPV Quantitative Typing assay
using the VALGENT framework. Intl Journal of Cancer .
2024;154(3):538-547. doi:10.1002/ijc.34754